Immunic Highlights 2023 Accomplishments and Upcoming Milestones
– Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis, Consistent Across the Entire Progressive Multiple Sclerosis Population and All Subtypes –
Related news for (IMUX)
- Immunic to Participate in Scientific and Investor Conferences in October
- Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
- Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dose Strengths in Progressive Multiple Sclerosis
- Immunic to Participate in Investor and Scientific Conferences in September
- Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update